The last November BioSeed Capital with headquarters in the Parc Científic of Barcelona established a new office in London to get access to UK’s market, one of the most powerful worldwide in healthcare startups, as well as in pharmaceutical firms.
Juan R. García, CEO of BioSeed Capital, explains how he sees this new business opportunity: “We work in a global sector where innovation requires an international presence for its commercialization. London is one of the most important centers worldwide in innovation and access to capital. We are sure that installing our headquarters there will help us to develop our international networking”.
The United Kingdom is a global center of excellence in Life Sciences and is the third most popular investment location in the world. Over £5 billion has been invested in the high-tech industries from the UK. Some data shows that nearly 750 companies of medical biotechnology are based in the UK with a combined turnover of £4.2 billion, representing an estimated 30% of European turnover in the sector. Furthermore, within these companies, 86% are engaged in research and development, resulting in innovation.
On another side, the pharmaceutical sector consists of around 600 companies with annual sales of around £15.6 billion, including big pharma’s headquarters of GlaxoSmithKline and AstraZeneca and other foreign companies with major presence in the UK including Pfizer, Novartis and Hoffmann-La Roche.
All this added to its university’s research excellence makes the United Kingdom in an essential spot in Europe to look for new markets.